SARCLISA® (isatuximab-irfc) | About Multiple Myeloma
What is SARCLISA? SARCLISA is a prescription medicine used in combination with: The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies …
Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma
Jan 7, 2025 · FDA recently approved Darzalex Faspro and Sarclisa combined with standard treatment regimens for people with newly diagnosed multiple myeloma.
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
Jun 3, 2024 · Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% …
Press Release: Sarclisa approved in the US as the first anti ... - Sanofi
Sep 20, 2022 · Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant ...
FDA Approves Sarclisa with VRd | Int'l Myeloma Foundation
Sep 20, 2024 · The IMROZ trial showed that when Sarclisa is added to Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone (VRd) in newly diagnosed multiple myeloma (NDMM) patients …
Sarclisa Subcutaneous Option for Myeloma - HealthTree for Multiple Myeloma
Jun 5, 2025 · Treatment Advances People with relapsed or refractory multiple myeloma may soon have a new, more convenient way to receive isatuximab (Sarclisa, Sanofi), a therapy already approved for …
Sarclisa: Uses, Dosage, Side Effects, Warnings - Drugs.com
Oct 4, 2024 · Sarclisa (isatuximab) is used for the treatment of multiple myeloma. Information includes Sarclisa side effects, warnings, interactions and indications.
Sarclisa (isatuximab): A New Option for Patients With Newly …
In September 2024, Sarclisa (isatuximab) became the first drug to be approved by the FDA for use with Velcade, Revlimid, and dexamethasone (Isa-VRd) for adult patients who are newly diagnosed with …
Summary report on authorisation – Sarclisa® - swissmedic.ch
3 days ago · Sarclisa was first authorised on 18 March 2020 in combination with pomalidomide and dexamethasone for the treatment of recurrent, treatment-resistant multiple myeloma in adults who …
Sanofi moves on J&J in first-line myeloma with FDA nod
Sep 20, 2024 · The FDA approved Sanofi's Sarclisa to be used with a popular treatment regimen in certain patients with previously untreated multiple myeloma.